Evaxion Biotech A/S is a pioneering TechBio company based upon its Artificial Intelligence (AI) platform: AI-Immunology™, which enables precise vaccine target discovery and optimization. The AI-Immunology™ platform consists of multiple proprietary AI prediction models harnessing the power of machine learning and artificial intelligence to decode the human immune system. This enables the development of novel vaccines for treatment of various cancers, bacterial and viral infections. To our knowledge, we are the first in the world to demonstrate a link between predictive power of AI and clinical response in patients as evidenced by a clear association between AI-Immunology™ predictions and progression free survival in metastatic cancer patients. Evaxion has developed a clinical-stage oncology pipeline of novel personalized therapeutic vaccines and a pre-clinical prophylactic vaccine pipeline for bacterial and viral diseases with high unmet medical needs based on AI-Immunology™.